- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07813468
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects (BT-HC034S-101)
A Phase I, Randomized, Double-Blind, Positive-Controlled, Parallel-Group Pharmacokinetic Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Xiaoai He
- Telefonnummer: +86-1500-897-1099
- E-post: 15008971099@126.com
Studieorter
-
-
Hainan
-
Haikou, Hainan, Kina, 570208
- Rekrytering
- Haikou People's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Subjects with allergic diathesis, or history of food/drug allergy within recent 4 weeks, especially hypersensitivity to any component of investigational product or excipients;
- Blood donation or substantial blood loss (>200 mL) within 3 months, or platelet donation within 2 weeks prior to investigational product administration;
- Major surgery within 6 months prior to first dosing, or planned surgery during study;
- Hereditary bleeding tendency, coagulation disorders, or history of thrombosis / hemorrhagic diseases;
- Prior treatment with EGFR-targeted agents;
- Use of prescription / over-the-counter drugs or nutritional supplements within 5 half-lives of the product OR within 2 weeks before study drug administration (whichever is longer). Discontinue traditional Chinese medicinal supplements 28 days prior to study drug administration, except for topical products with no systemic absorption.
- Clinically significant abnormalities as assessed by investigator in vital signs (SBP <90 mmHg or >140 mmHg; DBP >90 mmHg), physical examination, ECG (resting heart rate <50 or >100 beats/min), laboratory tests (blood biochemistry, CBC, urinalysis, coagulation);
- Presence of any investigator-identified clinically significant disease, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, cardiovascular and cerebrovascular disorders;
- History of hepatitis B, hepatitis C, AIDS, syphilis, or clinically significant abnormality in ≥1 item of infectious disease four-panel screening;
- Alcohol intake ≥14 units/week within 3 months pre-screening (1 unit = 285 mL beer, 25 mL 40%-ABV spirits, 150 mL 12%-ABV wine); alcohol-containing products consumed within 24 h prior to study drug dosing; positive alcohol breath test at screening;
- Cigarette smoking ≥5 cigarettes/day within 3 months pre-screening;
- Drug abuse history within 5 years, illicit drug use within 3 months before screening, habitual use of any medicines (including herbal medicines), or positive urine drug screen.
- Participation in any drug clinical trial with investigational product administration, or medical device trial receiving device treatment, or use of drugs of the same class within 3 months prior to screening;
- Receipt of live-attenuated vaccines within 14 days prior to first dosing, or planned live-attenuated vaccination during study;
- Intolerance to venipuncture blood collection, or history of needle-phobia or hematophobia;
- Any subject who, in investigator's judgment, may be unable to provide informed consent or follow the protocol; whose participation may bias study results or endanger subject safety; or otherwise considered unsuitable for study enrollment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HC034S
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first HC034S injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
|
Aktiv komparator: China-sourced Erbitux®
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first cetuximab injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Area under the serum concentration-time curve from time 0 to infinity (AUC0-∞)
Tidsram: Up to Day 29
|
Up to Day 29
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
quantifiable concentration (AUC₀-t)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Maximum serum concentration (Cmax)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Time to reach maximum serum concentration (Tmax)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Total clearance (CL)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Terminal elimination half-life (t1/2)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Apparent volume of distribution (Vd)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Apparent terminal elimination rate constant (λz)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Percentage of the area-under-the-curve extrapolated to infinity (AUC_%Extrap)
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) following study drug administration, including electrocardiograms (ECG), laboratory test parameters, physical examinations, and vital signs.
Tidsram: Up to Day 29
|
Up to Day 29
|
|
Positive incidence, titer and duration of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)
Tidsram: Up to Day 29
|
Up to Day 29
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HC034S-101
- BT-HC034S-101 (Annan identifierare: Shanghai Hongcheng Pharmaceutical Co., Ltd.)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .